AR053633A1 - Metodos para purificar proteinas que contienen una region fc - Google Patents

Metodos para purificar proteinas que contienen una region fc

Info

Publication number
AR053633A1
AR053633A1 ARP060102573A ARP060102573A AR053633A1 AR 053633 A1 AR053633 A1 AR 053633A1 AR P060102573 A ARP060102573 A AR P060102573A AR P060102573 A ARP060102573 A AR P060102573A AR 053633 A1 AR053633 A1 AR 053633A1
Authority
AR
Argentina
Prior art keywords
methods
region
polypeptides
proteins containing
purification
Prior art date
Application number
ARP060102573A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR053633A1 publication Critical patent/AR053633A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente solicitud provee métodos para la purificacion de polipéptidos que tienen una region Fc, por ejemplo, anticuerpos o anticuerpos de fusion, mediante la absorcion de los polipéptidos a un agente de union a Fc, tal como por ejemplo, una Proteína A, o una Proteína G, seguido de un lavado con un tampon de una sal de un cation divalente para retirar las impurezas, y la recuperacion posterior de los polipéptidos absorbidos. La presente solicitud también está caracterizada por métodos de elucion del polipéptido purificado así como por la incorporacion de los métodos en una serie de purificacion. También se proveen kits que comprenden los componentes e instrucciones para llevar a cabo los métodos.
ARP060102573A 2005-06-17 2006-06-16 Metodos para purificar proteinas que contienen una region fc AR053633A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69182105P 2005-06-17 2005-06-17

Publications (1)

Publication Number Publication Date
AR053633A1 true AR053633A1 (es) 2007-05-09

Family

ID=37433887

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP060102572A AR053632A1 (es) 2005-06-17 2006-06-16 Metoddos para purificar anticuerpos anti a beta
ARP060102573A AR053633A1 (es) 2005-06-17 2006-06-16 Metodos para purificar proteinas que contienen una region fc

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP060102572A AR053632A1 (es) 2005-06-17 2006-06-16 Metoddos para purificar anticuerpos anti a beta

Country Status (26)

Country Link
US (3) US7825223B2 (es)
EP (3) EP1896504B1 (es)
JP (2) JP5270337B2 (es)
KR (2) KR101247836B1 (es)
CN (3) CN101213211A (es)
AR (2) AR053632A1 (es)
AU (2) AU2006261185B2 (es)
BR (2) BRPI0611600B8 (es)
CA (2) CA2611815A1 (es)
CR (2) CR9582A (es)
EA (2) EA201100177A1 (es)
EC (1) ECSP088086A (es)
ES (2) ES2402650T3 (es)
HK (1) HK1117174A1 (es)
IL (2) IL187642A (es)
MA (1) MA29609B1 (es)
MX (2) MX2007015051A (es)
MY (1) MY144484A (es)
NI (1) NI200700329A (es)
NO (2) NO20076082L (es)
NZ (1) NZ565044A (es)
RU (1) RU2415865C2 (es)
SG (1) SG162806A1 (es)
TW (2) TWI372763B (es)
WO (2) WO2006138737A2 (es)
ZA (2) ZA200710331B (es)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7790856B2 (en) * 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
JP2006516639A (ja) * 2003-02-01 2006-07-06 ニユーララブ・リミテツド 可溶性Ａ−βに対する抗体を生成させるための能動免疫
TWI374893B (en) * 2003-05-30 2012-10-21 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
EA200700751A1 (ru) * 2004-10-05 2008-06-30 Элан Фарма Интернэшнл Лимитед Способы и композиции для улучшения продуцирования рекомбинантного белка
NZ554520A (en) * 2004-10-22 2010-03-26 Amgen Inc Methods for refolding of recombinant antibodies
CA2590337C (en) 2004-12-15 2017-07-11 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
KR101247836B1 (ko) * 2005-06-17 2013-03-28 와이어쓰 엘엘씨 항 ａ 베타 항체의 정제 방법
DK1976877T4 (en) 2005-11-30 2017-01-16 Abbvie Inc Monoclonal antibodies to amyloid beta protein and uses thereof
PT1954718E (pt) 2005-11-30 2014-12-16 Abbvie Inc Anticorpos anti-globulómeros aβ, suas porções de ligação ao antigénio, correspondentes hibridomas, ácidos nucleicos, vectores, células hospedeiras, métodos de produção dos ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos para uso dos ditos anticorpos
KR20150098683A (ko) * 2005-12-12 2015-08-28 에이씨 이뮨 에스.에이. 치료적 특성을 갖는 베타 1-42 특이적인 단일클론성 항체
US8784810B2 (en) * 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
WO2010044803A1 (en) * 2008-10-17 2010-04-22 Elan Pharma International Limited Treatment of amyloidogenic diseases
SG173385A1 (en) 2006-07-14 2011-08-29 Ac Immune S A Ch Humanized antibody against amyloid beta
PL2061803T5 (pl) * 2006-08-28 2023-03-27 Ares Trading S.A. Proces oczyszczania białek zawierających fc
CN101541825B (zh) * 2006-08-28 2013-08-14 阿雷斯贸易股份有限公司 Fc融合蛋白的纯化方法
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
SG174804A1 (es) 2006-09-13 2011-10-28 Abbott Lab
US8455626B2 (en) * 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008104386A2 (en) * 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
MX2009011127A (es) * 2007-04-18 2010-03-10 Janssen Alzheimer Immunotherap Metodo de prevencion y tratamiento de angiopatia amiloide cerebral.
US8003097B2 (en) * 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
JP2010528583A (ja) * 2007-06-11 2010-08-26 エーシー イミューン ソシエテ アノニム アミロイドβに対するヒト化抗体
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) * 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
RU2567151C2 (ru) * 2007-06-12 2015-11-10 Ац Иммуне С.А. Гуманизированные антитела к амилоиду бета
PT2182983E (pt) 2007-07-27 2014-09-01 Janssen Alzheimer Immunotherap Tratamento de doenças amiloidogénicas com anticorpos anti-abeta humanizados
SG185277A1 (en) * 2007-10-05 2012-11-29 Genentech Inc Humanized antibody
AU2008311367B2 (en) 2007-10-05 2014-11-13 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
AU2008311366B2 (en) * 2007-10-05 2015-03-12 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
LT2211904T (lt) * 2007-10-19 2016-11-25 Seattle Genetics, Inc. Cd19 surišantys agentai ir jų panaudojimas
KR20140015166A (ko) * 2007-10-30 2014-02-06 제넨테크, 인크. 양이온 교환 크로마토그래피에 의한 항체 정제
US20100233678A1 (en) * 2007-11-13 2010-09-16 Beadling Leslie C Tunable affinity ligands for the separation and detection of target substances
KR101247374B1 (ko) * 2008-06-26 2013-03-26 한국생명공학연구원 면역글로불린 Ｇ의 Ｆｃ 부위에 선택적으로 결합하는 신규펩타이드 및 그의 제조방법
US8592555B2 (en) 2008-08-11 2013-11-26 Emd Millipore Corporation Immunoglobulin-binding proteins with improved specificity
JP2012506239A (ja) * 2008-10-20 2012-03-15 アボット・ラボラトリーズ Ｉｌ−１８に結合する抗体およびそれを精製する方法
AU2009347206C1 (en) 2008-10-20 2016-12-08 Abbvie Inc. Isolation and purification of antibodies using Protein A affinity chromatography
SG10201702951RA (en) 2008-10-20 2017-06-29 Abbvie Inc Viral inactivation during purification of antibodies
CA2738243C (en) 2008-10-29 2020-09-29 Wyeth Llc Formulations of single domain antigen binding molecules
CA2739352C (en) 2008-10-29 2021-07-13 Wyeth Llc Methods for purification of single domain antigen binding molecules
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
CA2745707A1 (en) 2008-12-22 2010-07-01 F. Hoffmann-La Roche Ag Immunoglobulin purification
SG162687A1 (en) 2008-12-24 2010-07-29 Millipore Corp Caustic stable chromatography ligands
US8268820B2 (en) * 2009-03-26 2012-09-18 Hoffmann-La Roche Inc. 2,3-diaryl- or heteroaryl-substituted 1,1,1-trifluoro-2-hydroxypropyl compounds
PL2424889T3 (pl) 2009-04-30 2016-01-29 Ablynx Nv Sposób wytwarzania przeciwciał domenowych
EP3736338A1 (en) * 2009-09-01 2020-11-11 F. Hoffmann-La Roche AG Enhanced protein purification through a modified protein a elution
KR101632312B1 (ko) 2009-11-03 2016-06-21 삼성전자주식회사 항체 불변 영역에 특이적으로 결합하는 융합 단백질, 그의 제조 방법 및 이를 이용한 항체 분리 방법
JP2013516180A (ja) * 2009-12-31 2013-05-13 ミリアント・コーポレイション コハク酸アンモニウムを含有する発酵ブロスからのコハク酸の精製
JP5917417B2 (ja) * 2010-03-05 2016-05-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体の選択的強化
JP5814951B2 (ja) * 2010-03-10 2015-11-17 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 免疫グロブリン溶液を精製するための方法
MX360403B (es) 2010-04-15 2018-10-31 Abbvie Inc Proteinas de union a amiloide beta.
CN103179981B (zh) 2010-07-30 2017-02-08 Ac免疫有限公司 安全和功能性的人源化抗β‑淀粉样蛋白抗体
EP2603524A1 (en) 2010-08-14 2013-06-19 AbbVie Inc. Amyloid-beta binding proteins
KR20130139153A (ko) * 2011-01-18 2013-12-20 백스터 인터내셔널 인코포레이티드 인간 혈액 중 항-베타 아밀로이드 항체의 측정
ES2784628T3 (es) * 2011-03-29 2020-09-29 Glaxosmithkline Llc Sistema de tampón para purificación de proteína
SG10201604554WA (en) * 2011-06-08 2016-07-28 Emd Millipore Corp Chromatography matrices including novel staphylococcus aureus protein a based ligands
CN103827134A (zh) * 2011-07-20 2014-05-28 泽普泰恩股份有限公司 多肽分离方法
EP2768845B1 (en) * 2011-10-19 2017-01-18 Roche Glycart AG Separation method for fucosylated antibodies
CA2886036A1 (en) * 2012-09-25 2014-04-03 Glenmark Pharmaceuticals S.A. Purification of hetero-dimeric immunoglobulins
TWI596107B (zh) 2013-06-25 2017-08-21 卡地拉保健有限公司 單株抗體之新穎純化方法
CA2916566A1 (fr) 2013-07-05 2015-01-08 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Matrice de chromatographie d'affinite
NZ756750A (en) 2013-09-13 2022-05-27 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
JP2017520531A (ja) * 2014-06-02 2017-07-27 ラボラトワール フランセ デュ フラクショヌマン エ デ ビオテクノロジーＬａｂｏｒａｔｏｉｒｅ Ｆｒａｎｃａｉｓ ｄｕ Ｆｒａｃｔｉｏｎｎｅｍｅｎｔ ｅｔ ｄｅｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｉｅｓ Ｆｃ断片の産生
JP6451118B2 (ja) * 2014-07-17 2019-01-16 東ソー株式会社 抗体の分離方法
AR101262A1 (es) * 2014-07-26 2016-12-07 Regeneron Pharma Plataforma de purificación para anticuerpos biespecíficos
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
CN105175548B (zh) * 2015-08-13 2019-02-05 齐鲁制药有限公司 重组人血管内皮生长因子受体-抗体融合蛋白的纯化方法
CN107835819A (zh) * 2015-08-21 2018-03-23 豪夫迈·罗氏有限公司 在亲和层析中减少宿主细胞蛋白的方法
CN107849122B (zh) * 2015-08-21 2022-01-25 豪夫迈·罗氏有限公司 用低电导率洗涤缓冲液进行亲和层析纯化
EP3344643A4 (en) * 2015-09-04 2019-05-01 Qiagen Sciences LLC METHODS FOR CO-ISOLATION OF PROTEINS AND NUCLEIC ACIDS
GB201600161D0 (en) * 2016-01-05 2016-02-17 Bayer As Isotope purification method
GB201600154D0 (en) * 2016-01-05 2016-02-17 Bayer As Isotope preparation method
CN109311949B (zh) 2016-05-11 2022-09-16 思拓凡生物工艺研发有限公司 储存分离基质的方法
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
WO2017194593A1 (en) 2016-05-11 2017-11-16 Ge Healthcare Bioprocess R&D Ab Method of cleaning and/or sanitizing a separation matrix
CN109071613A (zh) 2016-05-11 2018-12-21 通用电气医疗集团生物工艺研发股份公司 分离基质
CN106519029B (zh) * 2016-10-31 2020-03-17 山东泰邦生物制品有限公司 一种Aβ寡聚体抗体的制备工艺
WO2018170488A1 (en) * 2017-03-17 2018-09-20 Gilead Sciences, Inc. Method of purifying an antibody
JP2018167260A (ja) * 2017-03-29 2018-11-01 三菱ケミカル株式会社 イオン交換体の保存方法、生理活性物質の精製装置及び生理活性物質の精製方法
WO2019036626A1 (en) * 2017-08-17 2019-02-21 Just Biotherapeutics, Inc. PROCESS FOR PURIFYING GLYCOSYLATED PROTEIN FROM GALECTINES AND OTHER HOST CELL CONTAMINANTS
US11447547B1 (en) 2017-12-13 2022-09-20 Amgen Inc. Method of antigen-binding protein production
CN109929038B (zh) * 2017-12-15 2020-10-09 山东博安生物技术有限公司 Vegf捕获剂融合蛋白的纯化方法
CN108048477A (zh) * 2017-12-15 2018-05-18 南京理工大学 基于大肠杆菌表达系统的制备多肽的方法
CN111902720A (zh) 2018-03-21 2020-11-06 沃特世科技公司 基于非抗体高亲和力的样品制备、吸附剂、装置和方法
US20220314142A1 (en) 2019-07-01 2022-10-06 Pfizer Inc. Improvements to wash solutions for protein a chromatography in an antibody purification process
CN112409477B (zh) * 2019-08-21 2022-11-08 广东菲鹏生物有限公司 IgM纯化方法
CN110724204B (zh) * 2019-11-18 2021-10-22 广东菲鹏制药股份有限公司 Fc融合蛋白的纯化方法
CN113968909A (zh) * 2020-07-22 2022-01-25 信达生物制药(苏州)有限公司 一种双特异性抗体的纯化方法
EP4185612A1 (en) 2020-07-23 2023-05-31 Othair Prothena Limited Anti-abeta antibodies

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
AU606320B2 (en) 1985-11-01 1991-02-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4801687A (en) * 1986-10-27 1989-01-31 Bioprobe International, Inc. Monoclonal antibody purification process using protein A
US4851341A (en) * 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
AU4308689A (en) 1988-09-02 1990-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
JP3068180B2 (ja) 1990-01-12 2000-07-24 アブジェニックス インコーポレイテッド 異種抗体の生成
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5112952A (en) * 1990-09-28 1992-05-12 Pierce Chemical Company Composition and method for isolation and purification of Immunoglobulin M
DK0564531T3 (da) 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
ATE363532T1 (de) 1991-03-01 2007-06-15 Dyax Corp Verfahren zur herstellung bindender miniproteine
ES2315612T3 (es) 1991-04-10 2009-04-01 The Scripps Research Institute Genotecas de receptores heterodimericos usando fagemidos.
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5786180A (en) 1995-02-14 1998-07-28 Bayer Corporation Monoclonal antibody 369.2B specific for β A4 peptide
AU8755798A (en) 1997-04-04 1998-11-13 Biosite Diagnostics Incorporated Polyvalent and polyclonal libraries
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6743427B1 (en) 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6710226B1 (en) 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US6750324B1 (en) * 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US20050059802A1 (en) 1998-04-07 2005-03-17 Neuralab Ltd Prevention and treatment of amyloidogenic disease
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
SK288711B6 (sk) 2000-02-24 2019-11-05 Univ Washington Humanizovaná protilátka, jej fragment a ich použitie, polynukleová kyselina, expresný vektor, bunka a farmaceutický prostriedok
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
DE60230736D1 (de) 2001-04-30 2009-02-26 Lilly Co Eli HUMANISIERTE ANTIKÖRPER DIE DAS BETA-AMYLOID PEPTID ERKENNEN& x9;
DE60229051D1 (de) 2001-04-30 2008-11-06 Lilly Co Eli Humanisierte antikörper
WO2003016466A2 (en) 2001-08-17 2003-02-27 Eli Lilly And Company ANTI-Aβ ANTIBODIES
US20060073149A1 (en) 2001-08-17 2006-04-06 Bales Kelly R Rapid improvement of cognition in condition related to abeta
CA2473144C (en) 2002-02-05 2013-05-28 Genentech, Inc. Protein purification
AR038568A1 (es) 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
JP2006516639A (ja) 2003-02-01 2006-07-06 ニユーララブ・リミテツド 可溶性Ａ−βに対する抗体を生成させるための能動免疫
US20040229330A1 (en) * 2003-02-27 2004-11-18 Bayer Pharmaceuticals Corporation Integrated method for capture and purification of tagged proteins
PT1601697E (pt) 2003-02-28 2007-09-04 Lonza Biologics Plc Purificação de anticorpos através de proteína a e cromatografia de troca iónica.
GB0304576D0 (en) 2003-02-28 2003-04-02 Lonza Biologics Plc Protein a chromatography
TWI374893B (en) 2003-05-30 2012-10-21 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
RU2409591C2 (ru) 2003-10-27 2011-01-20 Вайет Удаление агрегатов с высокой молекулярной массой путем хроматографии на гидроксиапатитах
HUE026000T2 (en) 2003-12-17 2016-04-28 Wyeth Llc Immunogenic peptide-bearing conjugates and methods for their preparation
SG182189A1 (en) 2003-12-17 2012-07-30 Elan Pharma Int Ltd A(beta) immunogenic peptide carrier conjugates and methods of producing same
US20050249723A1 (en) * 2003-12-22 2005-11-10 Xencor, Inc. Fc polypeptides with novel Fc ligand binding sites
AU2005260955A1 (en) 2004-07-14 2006-01-19 Astellas Pharma Inc. Agent for promoting the recovery from dysfunction after the onset of central neurological disease
EA200700751A1 (ru) 2004-10-05 2008-06-30 Элан Фарма Интернэшнл Лимитед Способы и композиции для улучшения продуцирования рекомбинантного белка
TW200636066A (en) 2004-12-15 2006-10-16 Elan Pharm Inc Humanized antibodies that recognize beta amyloid peptide
CA2590337C (en) 2004-12-15 2017-07-11 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
WO2006066171A1 (en) 2004-12-15 2006-06-22 Neuralab Limited Amyloid βετα antibodies for use in improving cognition
MX2007009091A (es) 2005-01-28 2008-01-11 Wyeth Corp Formulaciones de polipeptido liquidas estabilizadas.
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
KR101247836B1 (ko) * 2005-06-17 2013-03-28 와이어쓰 엘엘씨 항 ａ 베타 항체의 정제 방법
MX2009011127A (es) 2007-04-18 2010-03-10 Janssen Alzheimer Immunotherap Metodo de prevencion y tratamiento de angiopatia amiloide cerebral.
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
PT2182983E (pt) 2007-07-27 2014-09-01 Janssen Alzheimer Immunotherap Tratamento de doenças amiloidogénicas com anticorpos anti-abeta humanizados
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione

Also Published As

Publication number Publication date
IL187642A (en) 2014-08-31
US7825223B2 (en) 2010-11-02
EP2388274A1 (en) 2011-11-23
WO2006138553A2 (en) 2006-12-28
MY144484A (en) 2011-09-30
RU2415865C2 (ru) 2011-04-10
EP1896504A2 (en) 2008-03-12
EA200800083A1 (ru) 2008-06-30
US20070072307A1 (en) 2007-03-29
IL187683A0 (en) 2008-08-07
NZ565044A (en) 2010-05-28
US7820799B2 (en) 2010-10-26
WO2006138737A8 (en) 2007-12-13
KR101247836B1 (ko) 2013-03-28
IL187683A (en) 2015-02-26
JP2008543868A (ja) 2008-12-04
CA2611816C (en) 2014-05-27
ZA200710330B (en) 2009-12-30
SG162806A1 (en) 2010-07-29
EP1896506B1 (en) 2013-01-02
BRPI0611600A2 (pt) 2011-03-15
JP5270337B2 (ja) 2013-08-21
BRPI0611600B1 (pt) 2021-04-13
IL187642A0 (en) 2008-03-20
AU2006261185B2 (en) 2012-02-16
NO20076082L (no) 2007-12-27
BRPI0611600B8 (pt) 2021-05-25
KR20080023315A (ko) 2008-03-13
ECSP088086A (es) 2008-02-20
CN101213211A (zh) 2008-07-02
AU2006259298B2 (en) 2012-06-14
CN101365722A (zh) 2009-02-11
AR053632A1 (es) 2007-05-09
MA29609B1 (fr) 2008-07-01
CN104926938A (zh) 2015-09-23
AU2006261185A1 (en) 2006-12-28
CR9582A (es) 2008-05-05
HK1117174A1 (en) 2009-01-09
JP2008543881A (ja) 2008-12-04
BRPI0611599A2 (pt) 2011-02-22
WO2006138737A3 (en) 2007-03-22
ES2405079T3 (es) 2013-05-30
TW200840821A (en) 2008-10-16
MX2007015051A (es) 2008-01-18
WO2006138553A3 (en) 2007-02-22
TW200740839A (en) 2007-11-01
NI200700329A (es) 2015-04-21
NO20076056L (no) 2008-01-11
US20110160437A1 (en) 2011-06-30
ES2402650T3 (es) 2013-05-07
EP1896506A2 (en) 2008-03-12
ZA200710331B (en) 2009-04-29
KR20080059371A (ko) 2008-06-27
TWI372763B (en) 2012-09-21
CN104926938B (zh) 2019-06-04
EA015148B1 (ru) 2011-06-30
MX2007015952A (es) 2008-03-07
CA2611815A1 (en) 2006-12-28
AU2006259298A1 (en) 2006-12-28
US20070082367A1 (en) 2007-04-12
EA201100177A1 (ru) 2011-06-30
RU2007143162A (ru) 2009-08-10
KR101307614B1 (ko) 2013-09-13
US8440799B2 (en) 2013-05-14
WO2006138737A2 (en) 2006-12-28
JP5150488B2 (ja) 2013-02-20
CR9576A (es) 2008-03-06
CA2611816A1 (en) 2006-12-28
EP1896504B1 (en) 2012-11-21

Similar Documents

Publication Publication Date Title
AR053633A1 (es) Metodos para purificar proteinas que contienen una region fc
AR086525A1 (es) Metodo de purificacion de anticuerpos
AR069097A1 (es) Purificacion de anticuerpos por cromatografia de intercambio cationico
MX2019015304A (es) Amortiguador de lavado para cromatografia de intercambio cationico.
EA200970230A1 (ru) СПОСОБ ОЧИСТКИ Fc-СЛИТЫХ БЕЛКОВ
BR112013030628A2 (pt) "métodos para produção de uma proteína purificada de interesse utilizando uma matriz de cromatografia de afinidade (ca), e de um anticorpo purificado, fragmento de anticorpo ou proteína de fusão de fc utilizando a coluna de proteína a".
AR062570A1 (es) Proceso para la purificacion de las proteinas que contienen fc
TR201906652T4 (tr) Kademeli multimerize immünoglobülin fc bileşimleri oluşturmak için doğal insan protein fragmanları içeren füzyon proteinleri.
DK1568709T3 (da) Oprensning af fibrinogen
BR112014015101A2 (pt) cromatografia de membrana de troca iônica
BR112015014751A8 (pt) anti-corpos anti-tau humanos e fragmento de ligação a tau dos mesmo, seu uso na preparação de um medicamento, bem como polipeptídeos codificando os mesmos.
EA200800229A1 (ru) Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1)
RU2019109975A (ru) Способы очистки антител
BR112012015169A2 (pt) "preparação de fluxo com viscosidade dinâmica aumentada contendo k2alf5 desidratado, método para a produção do mesmo e método para o uso do mesmo."
BR112014032567A2 (pt) purificação de iduronato-2-sulfatase
MX2020006586A (es) Metodos para potenciar la eliminacion de impurezas durante una cromatografia con proteina a.
AR104358A1 (es) Método para la purificación de proteínas
BR0316476A (pt) Composição e processo para tratar nefrite do lúpus
EA201391605A1 (ru) Способы очистки вирусов с использованием гельпроникающей хроматографии
ATE439443T1 (de) NEUES Aß-BINDUNGSPROTEIN UND DESSEN PEPTIDDERIVATE SOWIE VERWENDUNGEN DAVON
RU2018138445A (ru) Способ очистки белка
AR076948A1 (es) Anticuerpos contra ccn1 (proteina rica en cisteina 61-cyr-61) humano y usos de los mismos
TH85813B (th) วิธีการในการทำให้เอฟซี รีเจียน (Fc Region) บริสุทธิ์ซึ่งประกอบด้วยโปรตีน
TH85813A (th) วิธีการในการทำให้เอฟซี รีเจียน (Fc Region) บริสุทธิ์ซึ่งประกอบด้วยโปรตีน
DE60143074D1 (de) Immunmodulation mit rezeptorinduziertem tod durch apoptosis

Legal Events

Date Code Title Description
FB Suspension of granting procedure